October 4, 2017
Houston, TX, USA and Munich, Germany – InGeneron announced today that Angelo Moesslang, PhD, former Chief Financial Officer (CFO) of Fresenius Medical Care North America, has joined InGeneron and will serve as the new Chief Executive Officer (CEO).
September 18, 2017
InGeneron announces publication of positive results from investigator-initiated wound healing case series using company’s regenerative cell technology
Houston, TX, USA and Munich, Germany – Point-of-care regenerative cell therapy demonstrates promising safety and tolerability profile and closure of venous chronic leg wounds as conducted by Technical University Munich.
March 6, 2017
Houston, Texas, and Sioux Falls, South Dakota – In addition to clinical trial cooperation with one of the largest U.S. hospital groups, investment will support clinical development in orthopedics and wound healing.
February 14, 2017
Houston, TX, USA – InGeneron, Inc. today announced changes in its leadership team. Michael Coleman, PhD, has stepped down as President and CEO and will join InGeneron’s Scientific Advisory Board. Ron Stubbers, MBA, formerly InGeneron’s Vice President of Operations, has been appointed President. The company also announced the appointment of Glenn Winnier, PhD, as Chief Scientific Officer.
December 5, 2016
InGeneron Establishes Presence in Cambridge, MA and Initiates Collaboration with German Accelerator Life Sciences
Cambridge, MA, USA and Berlin, Germany – InGeneron, a regenerative medicine and biotechnology company, today announced its acceptance to the German Accelerator Life Sciences (GALS) program, an initiative supported by the German Federal Ministry for Economic Affairs and Energy (BMWi).
November 21, 2016
InGeneron Announces Presentation of Results from Investigator Initiated Case Series of its Regenerative Cell Therapy in Chronic Back Pain at IFATS
Houston, TX, USA and Munich, Germany – InGeneron, Inc. today announced the presentation of initial data from an investigator initiated case series using its proprietary adipose-derived regenerative cell (ADRC) technology for the treatment of facet joint syndrome, one of the major causes of chronic back pain.